Nephrol Dial Transplant (2003) 18: 1427-1430
© 2003 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
The emerging role of VEGF in diabetic kidney disease
1 Medical Department M (Diabetes and Endocrinology), Medical Research Laboratories, Institute of Experimental Clinical Research, Aarhus University Hospital, Aarhus, Denmark and 2 Departments of Internal Medicine and the Diabetes Center, Hadassah University Hospital, Jerusalem, Israel and 3 Renal Unit, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium
Correspondence and offprint requests to: Allan Flyvbjerg, MD, DMSc, Medical Department M/Medical Research Laboratories, Institute of Experimental Clinical Research, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. Email: allan.flyvbjerg@dadlnet.dk
Keywords: advanced glycation endproduct; angio-tensin converting enzyme; antibody; experimental diabetes; type 1 and type 2 diabetes
| The first 150 words of the full text of this article appear below. |
Introduction
Micro- and macrovascular complications are the most important cause of increased morbidity and mortality in type 1 and type 2 diabetic patients. Early renal changes in diabetes are characterized by kidney enlargement, glomerular hyperfiltration and increased synthesis of extracellular matrix. Twenty-five to 40% of diabetic patients develop microalbuminuria with a high risk of progression to overt diabetic nephropathy. Several classes of growth factors and cytokines have been suggested to be involved in mediating the adverse vascular effects of hyperglycaemia, most importantly growth hormone, insulin-like growth factors, transforming growth factors ß and vascular endothelial growth factor (VEGF) [1–3]. Most recently the latter has been implicated in the pathogenesis of both diabetic nephropathy and retinopathy. Overall, VEGF appears to play a central role in mediating diabetic endothelial dysfunction and vasculopathy [2–4]. Increasing understanding of the molecular mechanisms underlying the role of VEGF in these
The VEGF system
Evidence for a role of VEGF in diabetic kidney disease
Treatments targeting VEGF
Conclusions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Orasanu and J. Plutzky The pathologic continuum of diabetic vascular disease. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S35 - S42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Korgaonkar, X. Feng, M. D. Ross, T.-c. Lu, V. D'Agati, R. Iyengar, P. E. Klotman, and J. C. He HIV-1 Upregulates VEGF in Podocytes J. Am. Soc. Nephrol., May 1, 2008; 19(5): 877 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Wang, S. X. Zhang, R. Mott, Y. Chen, R. R. Knapp, W. Cao, and J.-x. Ma Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1166 - F1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Toyoda, B. Najafian, Y. Kim, M. L. Caramori, and M. Mauer Podocyte Detachment and Reduced Glomerular Capillary Endothelial Fenestration in Human Type 1 Diabetic Nephropathy Diabetes, August 1, 2007; 56(8): 2155 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. X. Zhang, J. J. Wang, K. Lu, R. Mott, R. Longeras, and J.-x. Ma Therapeutic Potential of Angiostatin in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 475 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bocci, S. Man, S. K. Green, G. Francia, J. M. L. Ebos, J. M. du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Res., September 15, 2004; 64(18): 6616 - 6625. [Abstract] [Full Text] [PDF]
|
|